key: cord-0314414-qpkx9pde authors: Li, R.; Liu, H.; Fairley, C. K.; Ong, J. J.; Guo, Y.; Zou, Z.; Xie, L.; Zhuang, G.; Li, Y.; Shen, M.; Zhang, L. title: mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia date: 2022-05-10 journal: nan DOI: 10.1101/2022.05.08.22274797 sha: a678d4d103391b187c4ef8e7f4e1897c597ce9f6 doc_id: 314414 cord_uid: qpkx9pde Background: Australia implemented an mRNA-based booster vaccination strategy against the COVID-19 Omicron variant in November 2021. We aimed to evaluate the effectiveness and cost-effectiveness of the booster strategy over 180 days. Methods: We developed a decision-analytic Markov model of COVID-19 to evaluate the cost-effectiveness of a booster strategy (administered 3 months after 2nd dose) in those aged [≥]16 years in Australia from a healthcare system perspective. The willingness-to-pay threshold was chosen as A$ 50,000. Findings: Compared with 2-doses of COVID-19 vaccines without a booster, Australia's booster strategy would incur an additional cost of A$0.88 billion but save A$1.28 billion in direct medical cost and gain 670 quality-adjusted life years (QALYs) in 180 days of its implementation. This suggested the booster strategy is cost-saving, corresponding to a benefit-cost ratio of 1.45 and a net monetary benefit of A$0.43 billion. The strategy would prevent 1.32 million new infections, 65,170 hospitalisations, 6,927 ICU admissions and 1,348 deaths from COVID-19 in 180 days. Further, a universal booster strategy of having all individuals vaccinated with the booster shot immediately once their eligibility is met would have resulted in a gain of 1,599 QALYs, a net monetary benefit of A$1.46 billion and a benefit-cost ratio of 1.95 in 180 days. Interpretation: The COVID-19 booster strategy implemented in Australia is likely to be effective and cost-effective for the Omicron epidemic. Universal booster vaccination would have further improved its effectiveness and cost-effectiveness. The model consisted of 11 health states capturing the disease progression of COVID-19 ( Figure S1 ). A 115 vaccinated individual may be infected by SARS-CoV-2 and enter a 'latent infection state'. After a mean 116 incubation period of 5.2 (4. 1-7.0 ) days 24 , about 83% of infected individuals developed symptoms 25 , and the 117 remaining asymptomatic infections would spontaneously recover. A symptomatic infection might first exhibit 118 'mild/moderate' symptoms. They might then 'recover' or deteriorate to a 'severe' state. A patient in the 'severe' 119 state might 'recover' or progress to the 'critical' state. Similarly, a patient in the 'critical' state might 'recover' or 120 'die'. Transition probabilities between states were estimated using the formula = 1 − − , where r denoted 121 daily transition rate 25 . The basic model cycle length was 1 day, with a half-cycle correction applied. The costs of booster vaccination included the costs of the mRNA-based vaccine in Australia (A$53/dose) and 142 the vaccination administration ($20/dose) 28, 29 . The cost of PCR tests and rapid antigen self-test for COVID-19 143 infection was estimated to be A$85 and A$13 per person, respectively 30,31 . In addition, we collected the costs of 144 general practitioner (GP) consultation, general hospitalisation and ICU admission from published literature 32-34 . The cost of medical services varied across clinical disease stages 25,35-37 , and we calculated the total direct medical 146 cost of COVID-19 cases with varied severity by multiplying the unit cost of the medical services by the duration 147 of each disease stage (Appendix 1.5).Health utility scores for COVID-19 patients were derived from the disutility 148 weights of severe lower respiratory tract infection 38,39 and the estimates of pricing models for COVID-19 149 treatments published by the Institute for Clinical and Economic Review 40 (Appendix 1.6). We assumed a discount rate of 3% (0-6%) annually for both cost and quality-adjusted life-years (QALYs). We 152 calculated the incremental costs and incremental QALYs for booster vaccination strategy compared with no 153 booster (counterfactual scenario). The incremental cost-effectiveness ratio (ICER) was defined as the 154 incremental cost per QALY gained. We used a willingness-to-pay (WTP) threshold of ICER